deltatrials
Terminated PHASE3 NCT01536015

Effect of Rotigotine on Motor Symptoms in Patients With Advanced Parkinson's Disease (PD) With Motor Fluctuations and Symptoms of Gastrointestinal Dysfunction

A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Effect of Rotigotine on Motor Symptoms in Patients With Advanced Parkinson's Disease With Motor Fluctuations and Symptoms of Gastrointestinal Dysfunction

Sponsor: UCB Pharma

Conditions Advanced Parkinson's Disease
Interventions Placebo Rotigotine
Updated 6 times since 2017 Last updated: Jul 7, 2014 Started: Jan 31, 2012 Primary completion: Oct 31, 2013 Completion: Oct 31, 2013

This PHASE3 trial investigates Advanced Parkinson's Disease and is currently terminated or withdrawn. UCB Pharma leads this study, which shows 6 recorded versions since 2012 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE3

  3. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE3

  4. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE3

  5. Feb 2017 — Jun 2018 [monthly]

    Terminated PHASE3

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE3

    First recorded

Jan 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • UCB Pharma
Data source: UCB Pharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Annapolis, United States, Birmingham, United States, Charlotte, United States, Commack, United States, Cordova, United States, Fountain Valley, United States, Gainesville, United States, Gilbert, United States, Houston, United States, Irvine, United States and 16 more location s